BIO Statement Concerning the Recent Ruling Issued by the PTO’s Patent Trial and Appeal Board

Washington, D.C. (September 28, 2015) – The following statement may be attributed to the Biotechnology Industry Organization (BIO):

"It is disappointing that the PTO’s Patent Trial and Appeal Board (PTAB) failed to properly assess the important issues raised by this motion. This cursory and erroneous ruling reinforces the immediate need for Congress and the PTO leadership to take clear and decisive action to prevent any further misuse and abuse of the Inter Partes Review process by hedge funds, extortionists and other questionable entities seeking to undermine it for their own financial benefit."

Upcoming BIO Events 
 

###